Wall Street analysts forecast that Viewray Inc (NASDAQ:VRAY) will report earnings per share of ($0.18) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Viewray’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.22). Viewray reported earnings per share of ($0.21) in the same quarter last year, which would suggest a positive year-over-year growth rate of 14.3%. The business is scheduled to report its next earnings report on Tuesday, November 10th.
On average, analysts expect that Viewray will report full-year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.82) to ($0.65). For the next fiscal year, analysts expect that the company will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.80) to ($0.50). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Viewray.
Viewray (NASDAQ:VRAY) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The company had revenue of $14.22 million during the quarter, compared to the consensus estimate of $5.81 million. Viewray had a negative return on equity of 63.41% and a negative net margin of 166.74%.
Several analysts recently commented on the company. BidaskClub cut Viewray from a “hold” rating to a “sell” rating in a research report on Friday, August 28th. Oppenheimer restated a “buy” rating and issued a $3.00 target price on shares of Viewray in a research report on Tuesday, June 23rd. Cantor Fitzgerald assumed coverage on Viewray in a research report on Monday, June 15th. They issued a “buy” rating and a $3.00 target price on the stock. BTIG Research restated a “hold” rating on shares of Viewray in a research report on Wednesday, June 3rd. Finally, Zacks Investment Research upgraded Viewray from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Saturday, May 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $4.19.
Several hedge funds have recently modified their holdings of the company. Raymond James & Associates increased its holdings in shares of Viewray by 10.6% in the first quarter. Raymond James & Associates now owns 133,025 shares of the company’s stock valued at $333,000 after purchasing an additional 12,775 shares during the period. UBS Group AG increased its holdings in shares of Viewray by 1,020.3% during the first quarter. UBS Group AG now owns 118,034 shares of the company’s stock worth $295,000 after purchasing an additional 107,498 shares during the period. BlackRock Inc. increased its holdings in shares of Viewray by 32.1% during the first quarter. BlackRock Inc. now owns 7,200,179 shares of the company’s stock worth $17,999,000 after purchasing an additional 1,750,407 shares during the period. SG Americas Securities LLC increased its holdings in shares of Viewray by 77.2% during the first quarter. SG Americas Securities LLC now owns 37,555 shares of the company’s stock worth $94,000 after purchasing an additional 16,363 shares during the period. Finally, American International Group Inc. increased its holdings in shares of Viewray by 41.3% during the first quarter. American International Group Inc. now owns 62,399 shares of the company’s stock worth $156,000 after purchasing an additional 18,238 shares during the period. Institutional investors own 83.03% of the company’s stock.
VRAY traded up $0.02 during trading hours on Friday, hitting $2.78. The company’s stock had a trading volume of 589,520 shares, compared to its average volume of 821,715. Viewray has a fifty-two week low of $1.11 and a fifty-two week high of $4.88. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $411.29 million, a PE ratio of -3.12 and a beta of 0.78. The company has a 50-day simple moving average of $2.78 and a 200 day simple moving average of $2.38.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Featured Article: What member countries make up the G-20?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.